These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 36894916)

  • 21. Predictive Potential of Head and Neck Squamous Cell Carcinoma Organoids.
    Hill SJ; D'Andrea AD
    Cancer Discov; 2019 Jul; 9(7):828-830. PubMed ID: 31262743
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinoma.
    Leidner R; Crittenden M; Young K; Xiao H; Wu Y; Couey MA; Patel AA; Cheng AC; Watters AL; Bifulco C; Morris G; Rushforth L; Nemeth S; Urba WJ; Gough M; Bell RB
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963014
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma.
    Rebelatto MC; Midha A; Mistry A; Sabalos C; Schechter N; Li X; Jin X; Steele KE; Robbins PB; Blake-Haskins JA; Walker J
    Diagn Pathol; 2016 Oct; 11(1):95. PubMed ID: 27717372
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunotherapy in Patients with Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck.
    Łasińska I; Kolenda T; Teresiak A; Lamperska KM; Galus Ł; Mackiewicz J
    Anticancer Agents Med Chem; 2019; 19(3):290-303. PubMed ID: 30198439
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cancer stem cell related markers of radioresistance in head and neck squamous cell carcinoma.
    Kurth I; Hein L; Mäbert K; Peitzsch C; Koi L; Cojoc M; Kunz-Schughart L; Baumann M; Dubrovska A
    Oncotarget; 2015 Oct; 6(33):34494-509. PubMed ID: 26460734
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predictive value of quantitative diffusion-weighted imaging and 18-F-FDG-PET in head and neck squamous cell carcinoma treated by (chemo)radiotherapy.
    Martens RM; Noij DP; Koopman T; Zwezerijnen B; Heymans M; de Jong MC; Hoekstra OS; Vergeer MR; de Bree R; Leemans CR; de Graaf P; Boellaard R; Castelijns JA
    Eur J Radiol; 2019 Apr; 113():39-50. PubMed ID: 30927958
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Validation of a 15-gene hypoxia classifier in head and neck cancer for prospective use in clinical trials.
    Toustrup K; Sørensen BS; Metwally MA; Tramm T; Mortensen LS; Overgaard J; Alsner J
    Acta Oncol; 2016; 55(9-10):1091-1098. PubMed ID: 27161763
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intratumor heterogeneity could inform the use and type of postoperative adjuvant therapy in patients with head and neck squamous cell carcinoma.
    Mroz EA; Patel KB; Rocco JW
    Cancer; 2020 Jan; 126(9):1895-1904. PubMed ID: 32083741
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification and validation of a prognostic signature of autophagy, apoptosis and pyroptosis-related genes for head and neck squamous cell carcinoma: to imply therapeutic choices of HPV negative patients.
    Nan Z; Dou Y; Chen A; Wang K; Sun J; Meng Z; Neckenig M; Ai D; Liu S; Dong Z; Ma C; Cheng Y; Qu X
    Front Immunol; 2022; 13():1100417. PubMed ID: 36703967
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma.
    Van Allen EM; Lui VW; Egloff AM; Goetz EM; Li H; Johnson JT; Duvvuri U; Bauman JE; Stransky N; Zeng Y; Gilbert BR; Pendleton KP; Wang L; Chiosea S; Sougnez C; Wagle N; Zhang F; Du Y; Close D; Johnston PA; McKenna A; Carter SL; Golub TR; Getz G; Mills GB; Garraway LA; Grandis JR
    JAMA Oncol; 2015 May; 1(2):238-44. PubMed ID: 26181029
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epidermal growth factor receptor variant III in head and neck squamous cell carcinoma is not relevant for targeted therapy and irradiation.
    Thomas Koch D; Pickhard A; Gebel L; Buchberger AMS; Bas M; Mogler C; Reiter R; Piontek G; Wirth M
    Oncotarget; 2017 May; 8(20):32668-32682. PubMed ID: 28427242
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Blockade of adenosine A2A receptor enhances CD8
    Ma SR; Deng WW; Liu JF; Mao L; Yu GT; Bu LL; Kulkarni AB; Zhang WF; Sun ZJ
    Mol Cancer; 2017 Jun; 16(1):99. PubMed ID: 28592285
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination antiangiogenic therapy and radiation in head and neck cancers.
    Hsu HW; Wall NR; Hsueh CT; Kim S; Ferris RL; Chen CS; Mirshahidi S
    Oral Oncol; 2014 Jan; 50(1):19-26. PubMed ID: 24269532
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma.
    Hagemann J; Jacobi C; Gstoettner S; Welz C; Schwenk-Zieger S; Stauber R; Strieth S; Kuenzel J; Baumeister P; Becker S
    J Vis Exp; 2018 Apr; (134):. PubMed ID: 29733308
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immuno-oncology in head and neck squamous cell cancers: News from clinical trials, emerging predictive factors and unmet needs.
    Cavalieri S; Rivoltini L; Bergamini C; Locati LD; Licitra L; Bossi P
    Cancer Treat Rev; 2018 Apr; 65():78-86. PubMed ID: 29574334
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting EGFR-PI3K-AKT-mTOR signaling enhances radiosensitivity in head and neck squamous cell carcinoma.
    Horn D; Hess J; Freier K; Hoffmann J; Freudlsperger C
    Expert Opin Ther Targets; 2015 Jun; 19(6):795-805. PubMed ID: 25652792
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Integrated multi-omics analysis identifies CD73 as a prognostic biomarker and immunotherapy response predictor in head and neck squamous cell carcinoma.
    Shen A; Ye Y; Chen F; Xu Y; Zhang Z; Zhao Q; Zeng ZL
    Front Immunol; 2022; 13():969034. PubMed ID: 36466881
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunotherapy in head and neck squamous cell carcinoma: An updated review.
    Parmar K; Mohamed A; Vaish E; Thawani R; Cetnar J; Thein KZ
    Cancer Treat Res Commun; 2022; 33():100649. PubMed ID: 36279709
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A 13-gene expression-based radioresistance score highlights the heterogeneity in the response to radiation therapy across HPV-negative HNSCC molecular subtypes.
    Foy JP; Bazire L; Ortiz-Cuaran S; Deneuve S; Kielbassa J; Thomas E; Viari A; Puisieux A; Goudot P; Bertolus C; Foray N; Kirova Y; Verrelle P; Saintigny P
    BMC Med; 2017 Sep; 15(1):165. PubMed ID: 28859688
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Developments and future prospects of personalized medicine in head and neck squamous cell carcinoma diagnoses and treatments.
    Jayawickrama SM; Ranaweera PM; Pradeep RGGR; Jayasinghe YA; Senevirathna K; Hilmi AJ; Rajapakse RMG; Kanmodi KK; Jayasinghe RD
    Cancer Rep (Hoboken); 2024 Mar; 7(3):e2045. PubMed ID: 38522008
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.